Table 1.
Study Subjects, HIV-1 Isolates, and Summary of Long Terminal Repeat Clones
| Subject | Risk factor | Last CD4 count (cells/μl) | Antiretroviral(s) | HIV-1 encephalitis | Tissues yielding HIV-1 isolates | Name of virus isolate | LTRs cloned from virus isolate (n) | Unique LTRs (n) |
|---|---|---|---|---|---|---|---|---|
| CB1 | MH | 10 | ddI (prior AZT) | Severe | Brain | CB1-BR | 5 | 2 |
| CSF | CB1-CSF | 6 | 3 | |||||
| PBMC | CB1-PBMC | 6 | 3 | |||||
| CB3 | MH | 5 | ddI (prior AZT and ddC) | Severe | S.Cord | CB3-SC | 6 | 4 |
| CSF | CB3-CSF | 6 | 3 | |||||
| PBMC | CB3-PBMC | 6 | 3 | |||||
| MACS1 | MH | 2 | None | Severe | Brain | MACS1-BR | 6 | 3 |
| Spleen | MACS1-SP | 6 | 4 | |||||
| MACS2 | MH | 52 | AZT | Moderate | Brain | MACS2-BR | 6 | 5 |
| L.Node | MACS2-LN | 6 | 4 | |||||
| MACS3 | MH | 95 | None | Moderate | Brain | MACS3-BR | 6 | 6 |
| L.Node | MACS3-LN | 6 | 4 | |||||
| UK1 | IVDU | 87 | ddC (1 mo) | Moderate | Brain | UK1-BR | 6 | 2 |
| UK7 | IVDU | 90 | AZT | Severe | Brain | UK7-BR | 5 | 4 |
The clinical and neuropathological details of the study subjects and the derivation and characterization of the primary tissue-derived HIV-1 isolates have been published previously21,23,26 and are summarized again here to assist in the interpretation of the data derived from the cloned long terminal repeats (LTRs). LTRs were amplified from primary virus isolates by PCR and cloned into the pGL3-Basic vector to act as a promoter for the luciferase gene. The LTRs described here have been assigned GenBank accession numbers JX289943 to JX290024. MH, male homosexual; IVDU, intravenous drug user; mo, month; ddI, didanosine; AZT, zidovudine; ddC, zalcitabine; CSF, cerebrospinal fluid; PBMC, peripheral blood mononuclear cells; S.Cord, spinal cord; L.Node, lymph node.